Maintenance endocrine therapy prolonged progression-free survival of first-line chemotherapy with trastuzumab in advanced HR-positive, HER2-positive breast cancer patients.

	Maintenance endocrine therapy prolonged progression-free survival of first-line chemotherapy with trastuzumab in advanced HR-positive, HER2-positive breast cancer patients.
	Shen, Xia-Bo ; Wu, Jia-Yi ; Chen, Ke-Yu ; Fang, Zi-Ru ; Li, Guang-Liang ; Zou, Wei-Bin ; Wang, Xiaojia ; Shao, Xi-Ying
刊名	JOURNAL OF CLINICAL ONCOLOGY
	2022-06-01
卷号	40
ISSN号	0732-183X
WOS研究方向	Oncology
语种	英语
出版者	LIPPINCOTT WILLIAMS & WILKINS
WOS记录号	WOS:000863680302557
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/129785]
专题	中国科学院合肥物质科学研究院
作者单位	1.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Dept Breast Med Oncol, Canc Hosp, Hangzhou, Peoples R China 2.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Med Oncol Breast, Hangzhou, Peoples R China 3.Chinese Acad Sci, Inst Canc & Basic Med IBMC, Hangzhou, Peoples R China 4.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Hangzhou, Peoples R China 5.Univ Chinese Acad Sci, Canc Hosp, Hangzhou, Peoples R China 6.Zhejiang Canc Hosp, Hangzhou, Peoples R China
推荐引用方式 GB/T 7714	Shen, Xia-Bo,Wu, Jia-Yi,Chen, Ke-Yu,et al. Maintenance endocrine therapy prolonged progression-free survival of first-line chemotherapy with trastuzumab in advanced HR-positive, HER2-positive breast cancer patients.[J]. JOURNAL OF CLINICAL ONCOLOGY,2022,40.
APA	Shen, Xia-Bo.,Wu, Jia-Yi.,Chen, Ke-Yu.,Fang, Zi-Ru.,Li, Guang-Liang.,...&Shao, Xi-Ying.(2022).Maintenance endocrine therapy prolonged progression-free survival of first-line chemotherapy with trastuzumab in advanced HR-positive, HER2-positive breast cancer patients..JOURNAL OF CLINICAL ONCOLOGY,40.
MLA	Shen, Xia-Bo,et al."Maintenance endocrine therapy prolonged progression-free survival of first-line chemotherapy with trastuzumab in advanced HR-positive, HER2-positive breast cancer patients.".JOURNAL OF CLINICAL ONCOLOGY 40(2022).